n early diagnosis of myocardial infarction facilitates rapid decision making and treatment and therefore improves the outcome in patients presenting with symptoms of chest pain. 1, 2 The introduction of the testing of necrosis markers in the emergency setting constituted a milestone in the care of patients with chest pain. [3] [4] [5] [6] Guidelines recommend the measurement of cardiac troponin levels for the diagnosis of myocardial infarction, with a level above the 99th percentile in a reference population as the discriminatory value, including the detection of a rise or fall in the troponin levels. [7] [8] [9] Although conventional necrosis markers have a high diagnostic value, their sensitivity is weak within the first hours after the onset of chest pain.
To overcome this limitation, a new generation of sensitive assays for cardiac troponins with a 10% coefficient of variation for levels below the 99th percentile has been introduced recently. [10] [11] [12] [13] [14] [15] [16] [17] This cadre of sensitive troponin assays might further enhance the accuracy of the diagnosis of myocardial infarction and therefore improve diagnostic sensitivity and specificity, even in patients presenting early after the onset of chest pain. There are few data from large-scale prospective studies assessing the use of such assays for the early diagnosis of myocardial infarction. We therefore evaluated the diagnostic accuracy, discrimination, and clinical usefulness of a sensitive troponin I assay for the early diagnosis and risk stratification of myocardial infarction in a large prospective, multicenter study involving patients with chest pain who had a high pretest probability of acute myocardial infarction.
Me thods

Study Population
From January 2007 through December 2008, we enrolled 1818 consecutive patients presenting with new-onset chest pain at chest-pain units at three German study centers -the Johannes Gutenberg University Medical Center in Mainz, the Federal Armed Forces Hospital in Koblenz, and University Hospital Hamburg-Eppendorf in Hamburg -in a biomarker-assessment registry. A detailed description of the study population is provided in the Methods section of the Supplementary Appendix, available with the full text of this article at NEJM.org.
Study Oversight
The study was approved by local ethics committees in Rheinland-Pfalz and Hamburg. All patients provided written informed consent. The investigational assay of troponin I (Troponin I Ultra) was purchased from Siemens Healthcare Diagnostics, which had no role in the design of the study, the analysis of the data, or the preparation of the manuscript.
Adjudication of the Final Diagnosis
The final discharge diagnosis, which was based on all available clinical, laboratory, and imaging findings, was adjudicated by an expert committee of two independent cardiologists who were unaware of the results of the troponin I assays. If there was disagreement about the final diagnosis, a third cardiologist refereed.
Diagnosis Based on Conventional Troponin Assays
A primary diagnosis of acute myocardial infarction was adjudicated according to current guidelines when there was evidence of myocardial necrosis that was consistent with myocardial ischemia, together with clinical symptoms of ischemia or electrocardiographic changes indicative of new ischemia (new ST-segment or T-wave changes or new left bundle-branch block) or imaging evidence of new loss of viable myocardium or detection of a culprit lesion on coronary angiography; the latter was classified according to the Ambrose criteria. 18 Myocardial necrosis was documented if there was at least one value above the cutoff value for 10% imprecision of the respective conventional troponin test together with a rising or falling pattern of at least 20% within 6 hours after admission to distinguish background elevated troponin levels from acute elevation. Conventional troponin assays that were used for the adjudication of the final diagnosis were Roche Troponin T in Mainz and Hamburg (with a cutoff value for 10% imprecision of 0.03 ng per milliliter) and Siemens Dimension RxL Troponin I in Koblenz (with a cutoff value for 10% imprecision of 0.14 ng per milliliter). The conventional troponin I assay was used only for the diagnosis of myocardial infarction and not for comparisons with the sensitive troponin I assay. Unstable angina pectoris was diagnosed if the electrocardiogram was not diagnostic and if serial conventional troponin testing was negative but ischemia was proved by the To assess the diagnostic value of the sensitive troponin I assay used alone, and to determine how soon a diagnosis could be made on the basis of the assay result, we also used a refined approach for the diagnosis of acute myocardial infarction. First, we used the sensitive troponin I assay in 5000 population-based subjects in the Gutenberg Heart Study and determined that a value of 0.04 ng per milliliter was the 99th percentile for that population. (Fig. 1 With the use of both criteria, we classified all patients who had an elevated troponin level from causes other than coronary origin as having noncoronary chest pain, including 19 patients with proven pulmonary embolism, 18 patients with acute decompensated heart failure, 17 patients with myocarditis, 6 patients with aortic dissection, and 2 patients with decompensated aorticvalve stenosis, as well as all other patients who had no indication of myocardial infarction on the basis of troponin measurements, electrocardiography, coronary angiography, or stress testing. The relatively low number of patients with decompensated heart failure was explained by the primary admission of such patients to the general emergency department.
Statistical Analysis
We calculated receiver-operating-characteristic (ROC) curves on the basis of the continuously measured biomarker levels by taking every measured biomarker level as a cutoff value and then deriving sensitivity and specificity values from the resulting two-by-two tables for each cutoff value. This procedure was repeated for every combination of biomarkers and times of chest-pain onset. The area under the ROC curve (AUC) was calculated with the use of the R package Epicalc.
In addition, we assessed sensitivity, specificity, and positive and negative predictive values for the target markers by applying a marker-specific cutoff value and consecutively calculating the corresponding values from a two-by-two factorial design. Cox regression models were used to determine the association of troponin I levels as measured with the sensitive assay and troponin T levels with the outcome at 30 days. Two models were specified, one adjusted for sex and age and one additionally adjusted for body-mass index; the presence or absence of hypertension, diabetes mellitus, and hyperlipidemia; smoking status; the estimated glomerular filtration rate; and electrocardiographic results. The resulting hazard ratios reflect the risk of an event if biomarker values exceeded the corresponding cutoff value. P values are based on the Wald z-test statistic. All statistical analyses were performed with the use of R software (version 2.8.1) and SAS software (version 9.2). (A detailed description is available in the Methods section of the Supplementary Appendix.)
R esult s
Baseline Characteristics of the Patients
Baseline characteristics of the overall study population at admission to the chest-pain unit are provided in Table 1 . The final discharge diagnosis of acute myocardial infarction was made in 413 of 1818 patients (22.7%), including 130 patients (7.2%) who presented with myocardial infarction with ST-segment elevation. The distribution of the time of chest-pain onset was similar in all diagnosis groups. The distribution of troponin T and troponin I values, according to the discharge diagnosis and serial sampling, is shown in Figure 2 in the Supplementary Appendix. cardial infarction, as compared with conventional troponin T measurement and traditional markers of necrosis. Biomarkers were treated as continuous variables and analyzed according to the time of chest-pain onset. The diagnostic accuracy of the sensitive troponin I assay was highest, with an AUC of 0.95 in patients presenting within 3 hours after the onset of chest pain; this value increased marginally, to 0.96, in patients presenting within 6 or 12 hours after chest-pain onset. To assess the diagnostic accuracy over time, serial assays were performed at baseline and at 3 hours and 6 hours after admission (Fig. 3 in the Supplementary Appendix). For discriminatory analyses of the sensitive troponin I assay, we applied the locally determined upper reference limit of 0.04 ng per milliliter. With testing on admission, the clinical sensitivity for the sensitive troponin I assay was 90.7%, and the specificity was 90.2%, regardless of the interval between the onset of chest pain and admission (Table 2) .
A total of 240 of the 1818 patients (13.2%) presented with unstable angina. Of these patients, 53 (22.1%) had troponin I levels of more than 0.04 ng per milliliter as measured with the sensitive assay. With the use of this assay to differentiate unstable angina from noncoronary chest pain, the AUC was 0.62, with a negative predictive value of 84.8%.
Alternative Definition of Myocardial Infarction
As an alternative diagnostic approach, we defined acute myocardial infarction on the basis of a troponin I level, as measured with the sensitive assay, that was above the 99th percentile value of 0.04 ng per milliliter, together with a rise or fall in the level of 30% or more within 3 or 6 hours after hospital admission. We first tested the probability of predicting the rising pattern with the initial sensitive-assay value and calculated the AUC according to the alternative definition of myocardial infarction. Figure 2 shows the association between an elevated value on admission and the diagnosis of acute myocardial infarction, according to the time of chest-pain onset. In patients presenting within 3 hours after the onset of chest pain, 184 of 227 patients with diagnosed myocardial infarction (81.1%) had a single troponin I level of more than 0.04 ng per milliliter on admission, for a negative predictive value of 84.1% and a positive predictive value of 86.7%. Overall, the AUC of the baseline troponin I level was approximately 0.90, regardless of the time of chest-pain onset.
Second, we calculated the time it took to diagnose myocardial infarction in 95 to 100% of patients using the sensitive troponin I assay (Table 3) . A total of 88% of myocardial infarctions were detected on admission in patients presenting within 6 hours after the onset of chest pain, and 95% of myocardial infarctions were detected in those presenting between 6 and 12 hours after the onset of chest pain. With serial measurements (on admission and 3 or 6 hours after admission), the rate of detection of myocardial infarction was 100%.
Low or Moderate Troponin I Levels
Of 585 patients in whom troponin I levels, as measured with the sensitive assay, were between the limit of detection (0.006 ng per milliliter) and the 99th percentile (0.04 ng per milliliter) on admission, 115 patients (19.7%) had levels of more than 0.04 ng per milliliter within 6 hours after hospital admission. Of these patients, only 30 were categorized as having acute myocardial infarction on the basis of conventional troponin measurement; in 29 of the 30 patients, myocardial infarction was confirmed angiographically. A total of 87 patients had moderately elevated troponin I levels (>0.04 ng per milliliter) without a rise or fall of 30% in subsequent samples. Of these patients, 62 had a distinct noncoronary diagnosis ( Table 1 in the Supplementary Appendix); none of the 62 patients had an adverse event during the 30-day follow-up.
Short-Term Outcome
Measurements with both the sensitive troponin I assay and the conventional troponin T assay predicted the risk of major cardiovascular events within 30 days after presentation. For details, see Table 2 in the Supplementary Appendix.
Discussion
In our study, serial testing in 1818 consecutive patients with chest pain established that a single sensitive troponin I assay at the time of admission, as compared with a conventional troponin T assay and other markers of myocardial necrosis, provided substantially improved levels of diagnostic accuracy and discrimination for the early diagnosis of myocardial infarction. These findings also point to the clinical significance of very low detectable levels of troponin release. The use of the sensitive troponin I assay has two major clinical implications. First, a single value, obtained on admission, of more than the 99th percentile reference value provided very high levels of accuracy and discrimination for the diagnosis of myocardial infarction, with an AUC of 0.96, as compared with conventional troponin assays. Second, with the alternative definition of myocardial infarction on the basis of the sensitive troponin I assay, the measurement obtained on admission still had a high diagnostic accu- racy, with a diagnostic rate for myocardial infarction of 88% for patients who presented within 6 hours after the onset of chest pain, 95% for those who presented from 6 to 12 hours after the onset, and 100% for those who presented more than 12 hours after the onset. Measurement of the troponin I level with the use of the sensitive assay within 3 hours after admission ensured a 100% rate of detection of myocardial infarction. The results of our study extend the findings of two recent single-center pilot studies, 10,12 which showed that with the use of the sensitive troponin I assay, the pattern of a rising troponin I level over time can be predicted from a single sample obtained on admission.
In the absence of clinical evidence of ischemia, an elevated cardiac troponin level should prompt the search for other causes of myocardial necrosis, such as myocarditis, pulmonary embolism, congestive heart failure, renal failure, and aortic-valve disease. However, as in other studies, 17,19 our data provide persuasive evidence that rising troponin I values as measured with sensitive assays, a pattern that reliably establishes the diagnosis of myocardial infarction, can be predicted with a high degree of diagnostic accuracy if the initial value exceeds the upper reference limit for the 99th percentile. Since troponin I levels rise above the upper reference limit of 0.04 ng per milliliter in approximately 20% of patients who present with a lower level, serial testing after 3 hours is also recommended in this subgroup.
For the conventional troponin T assay, we selected a 20% difference between serial troponin T levels to establish the diagnosis of myocardial infarction, since the change represented twice the recommended maximum imprecision (a coefficient of variation of 10%) for that troponin assay. Therefore, changes in the level are unlikely to have been due to analytic imprecision. 20 By contrast, for the sensitive troponin I assay, we selected a difference of 30% to establish the alternative diagnosis of myocardial infarction, since the use of such a differential (in addition to either the baseline or follow-up level) has been shown to improve both diagnostic specificity and risk assessment in patients presenting with chest pain. 19 One of the strengths of our study was that prospective serial sampling was performed under standardized conditions in consecutive patients with chest pain who had a high pretest probability of myocardial infarction. This approach allowed for the optimal use of all biomarker measurements. The current guidelines established the 99th percentile of a normal reference population as the diagnostic decision limit for myocardial infarction. Selection of the reference population might influence the determination of the 99th percentile. 21 Therefore, we established and confirmed the upper reference limit of 0.04 ng per milliliter in an independent, population-based study involving 5000 patients and applied this value for the discriminatory analyses. Shown is the area under the receiver-operating-characteristic curve (AUC) for the sensitive troponin I assay (troponin I) and a standard troponin T assay, according to the time of chest-pain onset. Criteria for the diagnosis of myocardial infarction with the use of the sensitive troponin I assay were a level of more than 0.04 ng per milliliter within 6 hours after admission and a rise or fall of at least 30% in the level. In addition, the number of patients in whom acute myocardial infarction was diagnosed and the number of patients who were identified as having acute myocardial infarction by means of a single measurement of troponin I (sensitive assay) or troponin T are given for the corresponding time points. AMI denotes acute myocardial infarction. Several limitations of our study merit consideration. The conventional troponin T assay does not fulfill the requirement of a coefficient of variation of less than 10% at the 99th percentile. Thus, we established a cutoff at the level of the 10% coefficient of variation. This approach might have accentuated the difference of the observed results between the conventional troponin T assay and the sensitive troponin I assay. Troponin I levels are known to be affected by age and renal function. Better sensitivity may thus lead to a higher rate of false positive results. However, the specificity of the new sensitive assays has also increased, for which our data provide persuasive evidence. 11-14 The current investigational assay represents an entire generation of contemporary assays with a 10% coefficient of variation below the 99th percentile population distribution. Finally, whether the classification of unstable angina pectoris will still be necessary in the era of sensitive troponin testing will require further study.
In conclusion, initial use of the sensitive troponin I assay substantially improved the early diagnosis of myocardial infarction and helped to safely rule out or rule in coronary causes of acute chest pain. Future studies will be needed to determine whether the early diagnosis of myocardial infarction facilitates rapid use of invasive strategies and thus improves the outcome in patients with myocardial infarction.
